IBSA USA
David Mason is an accomplished Endocrinology & Pain Specialist at IBSA USA since December 2022. With extensive experience in specialty sales, David previously held roles at GSK as a Senior Specialty Sales Representative focusing on respiratory sales, achieving top territory performance. At Amgen, responsibilities included planning and executing a successful product launch for Aimovig, while also developing strategic business plans. David’s career also includes significant achievements at Boehringer Ingelheim, Be The Match, Alcon Labs, Boise Paper, and Nestlé Waters North America, where a consistent record of sales growth and leadership roles was established. David holds a BS in Business Administration from the University of New Hampshire.
This person is not in the org chart
This person is not in any teams
IBSA USA
IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies. IBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions. IBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility. For more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.